AI Data Insight
In the first quarter of 2026, U.S. imports of medicinal, dental, and pharmaceutical products fell to 38,563 million USD, a significant decline from the previous value of 50,870 million USD, continuing the downward trend since the massive volume recorded early last year. As the U.S. government officially imposes import tariffs of up to 100% on patented drugs and strongly promotes the reshoring of supply chains to the mainland, the inventories built up in advance by multinational pharmaceutical giants have begun to destock, driving a rapid contraction in import data.